Clinical Trials Logo

Citation(s)

  •   Haig GM, Wang D, Zhao J, Othman AA, Bain EE
    Efficacy and Safety of the a7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smok

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers

Details for clinical trial NCT01678755